Brief: Opus Genetics Announces Updates On Opgx-Lca5 Clinical Program
Feb 18 (Reuters) - Opus Genetics Inc IRD.O :
* OPUS GENETICS ANNOUNCES UPDATES ON OPGX-LCA5 CLINICAL
PROGRAM
* OPUS GENETICS INC: FDA MEETING SCHEDULED IN MARCH 2025 TO
DISCUSS PHASE 3 TRIAL DESIGN AND REGISTRATIONAL ENDPOINTS FOR
OPGX-LCA5
* OPUS GENETICS INC: INITIAL DATA ON COHORT ANTICIPATED BY
Q3 2025
Source text: ID:nGNX96nTcP
Further company coverage: IRD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data